ClinicalTrials.gg
RecruitingNCT05312255Updated Nov 9, 2026

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

An interventional study of Behavioral Intervention and Beta-Adrenergic Antagonist in Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma and Refractory Plasma Cell Myeloma, sponsored by Roswell Park Cancer Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Roswell Park Cancer Institute · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 4 months later.
Updated Nov 9, 2026Enrollment updatedEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
265
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 21 studies in Multiple Myeloma by Roswell Park Cancer Institute — 3 open to participants now, 6 under way, none of them phase 3. Multiple Myeloma · Roswell Park Cancer Institute.

Planned enrollment
2nd of 21
265 · median 31
Started
2022
the only one that year
No phase
6 of 21
1 open now
Registered
18th of 21
by date

Among the 21 studies in Multiple Myeloma by Roswell Park Cancer Institute, this one is the 2nd largest by planned enrollment, is the only one that started in 2022, is one of 6 with no phase, and was the 18th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

3 of the 21 studies in Multiple Myeloma by Roswell Park Cancer Institute are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Multiple Myeloma by Roswell Park Cancer Institute, or all of them as a file.
02

Study summary

This clinical trial investigates the effect of non-chemotherapeutic interventions in patients with multiple myeloma or MDS. Non-chemotherapeutic interventions such as physical activity and nutritional interventions (e.g., modifications in diet) have been shown to positively affect the immune system and improve overall quality of life. Another purpose of this study is for researchers to learn how the addition of a beta-blocker (propranolol) to the standard treatment regimen in patients with newly diagnosed multiple myeloma affects immune response and quality of life. A study from the Mayo Clinic looked at multiple myeloma patients who were on a beta-blocker while undergoing chemotherapy and found that the use of a beta-blocker resulted in improved patient survival outcomes. Non-chemotherapeutic treatment options may help decrease symptoms and improve quality of life for patients with multiple myeloma.

Read the detailed description

PRIMARY OBJECTIVES:

I. To assess the impact of different lifestyle and low side effect interventions (exercise, nutrition, stress effects reduction) on immune markers in patients with monoclonal plasma cell and other hematologic disorders.

SECONDARY OBJECTIVES:

I. To assess the impact of different lifestyle and low side effect interventions (exercise, nutrition) on bone turnover parameters, body composition, the microbiome and physical fitness in patients with monoclonal plasma cell and other hematologic disorders.

II. To assess the impact of different lifestyle and low side effect interventions (exercise, nutrition, stress effect reduction) on parameters of stress, mental health and quality of life in patients with monoclonal plasma cell and other hematologic disorders.

OUTLINE: Patients are assigned to Module A, B C , D. (MDS patients will only be assigned in Module D) or E.

MODULE A: Patients undergo strength training sessions twice weekly supervised by a licensed and specialized personal trainer via the internet (e.g., remote access) for 6 months. Patients also wear a FitBit device and receive prompts via email or text on a cell phone or other electronic device to incrementally increase physical activity over 6 months.

MODULE B: Patients undergo intermittent fasting for 1 month. This consists of restricting all eating to a consecutive 8-hour time period each day followed by 16 consecutive hours of not eating.

MODULE C: Patients are assigned to group 1 (are not currently taking beta-blockers) or group 2 (current taking beta-blockers).

GROUP I: Patients receive propranolol orally (PO) twice daily (BID) for 3 months.

GROUP II: Patients continue receiving beta-blocker regimen as per standard of care (SOC) for 3 months.

MODULE D: Patients will receive resistance training twice a week for 6 months.

MODULE E: Patients undergo resistance training sessions twice weekly supervised by a licensed and specialized personal trainer via the internet (e.g., remote access) for 9 months. Patients also wear a FitBit device and receive prompts via email or text on a cell phone or other electronic device to incrementally increase physical activity over 9 months. Patients also undergo DEXA scans on study and collection of blood samples and bone marrow biopsy (as indicated for clinical care) throughout the trial

After completion of the study interventions, patients in module A and D are followed every 3 months for 1 year. Patients in module B are followed at 3 and 5 months. Patients in modules C and E are followed for 3 months.

03

Conditions studied

  • Plasma Cell Myeloma
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Smoldering Plasma Cell Myeloma
04

Who can participate

The criteria were revised on the registry on Nov 9, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 18 years of age
  • Have an (ECOG) Performance Status of:

    • Module A: ECOG 0 - 1
    • Module B: ECOG 0 - 2
    • Module C: ECOG 0 - 2
    • Module D: ECOG 0-1
    • Module E: ECOG 0-1
  • MODULE A -C: Have a diagnosis of smoldering multiple myeloma, multiple myeloma or plasma cell leukemia (PCL) or
  • MODULE D: non transfusion dependent low-risk MDS
  • Show no signs of comorbidities, myeloma symptoms, or treatment side effects that would put them in danger when participating in the study according to the physician's discretion
  • Are able to understand and follow assessment and intervention procedures
  • Participant must understand the nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written form prior to receiving any study related procedure
  • MODULE A, D and E: (PHYSICAL ACTIVITY): Participant has access to a personal computer or tablet with camera, microphone, speakers and internet access
  • MODULE B (NUTRITION): Not applicable
  • MODULE C (BETA BLOCKER): Newly diagnosed patients with multiple myeloma necessitating treatment and before initiation of systemic therapy
  • MODULE C: Female participants of must have a negative pregnancy test at study entry and then agree to use adequate methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Male patients with female partners of child-bearing potential should also use adequate contraceptive methods (see above). Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately MODULE D (PHYSICAL ACTIVITY): Patients with MDS not necessitating transfusion therapy at time of enrollment (no transfusion within 8 weeks prior to enrollment) i.e. patients on observation, or receiving growth factors or luspatercept only

    • MODULE E (EX-MT): Have a planned stem cell transplant (ASCT) for front line therapy
    • MODULE E (EX-MT): Be enrolled in the Biorepository and Laboratory Services (BLS) Universal Consent with completed epidemiological questionnaire
    • MODULE E (EX-MT): Report being inactive or low active during the peri-diagnosis and treatment period leading up to study enrollment
    • MODULE E (EX-MT): Participant has access to a personal computer or tablet with camera, microphone, speakers and internet access
    • MODULE E (EX-MT): Receive appropriate medical clearances to exercise

Exclusion criteria

Exclusion Criteria:

  • Major comorbidities that would cause danger to the patient when participating in the study and that would have a risk of progression if the patient took part in the study (including, but not limited to): cardiac or pulmonary and infectious diseases (e.g., ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia) or, psychiatric illness/social situations that would limit compliance with study requirements
  • Unwilling or unable to follow protocol requirements
  • Any condition which in the investigator's opinion deems the participant an unsuitable candidate to take part in study intervention (comorbidities, myeloma symptoms, treatment side effects)
  • MODULE A and E:(PHYSICAL ACTIVITY): Current and symptomatic pathological fracture(s) or severely advanced instability of the musculo-skeletal system that is deemed to making the patient unsafe to participate. This will be assessed by radiologist, a neurosurgeon and/or an orthopedic surgeon, if applicable.
  • MODULE A and E: (PHYSICAL ACTIVITY): Current and symptomatic pathological fracture(s) or severely advanced instability of the musculo-skeletal system
  • MODULE A and E: (PHYSICAL ACTIVITY): Acute bone instability as assessed by whole body low-dose computed tomography and evaluated by an experienced surgeon
  • MODULE B (NUTRITION): Clinical signs of malnutrition ( [BMI] \< 18)
  • MODULE B (NUTRITION): Special diets (physician prescribed)
  • MODULE B (NUTRITION): Diabetic treated with glucose-lowering medications and/or insulin
  • MODULE B (NUTRITION): Other reasons not to withhold food
  • MODULE B (NUTRITION): Any condition which in the investigator's opinion deems the participant an unsuitable candidate to limit food consumption
  • MODULE C (BETA BLOCKER): Current use of a beta blocker (includes all non-selective and beta-1 selective blockers) or, use of a beta-blocker within 3 months of study enrollment
  • MODULE C (BETA BLOCKER): to the use of beta-blockers, e.g.; severe sinus bradycardia; sick sinus syndrome; or heart block greater than first-degree, uncontrolled depression, unstable angina pectoris, uncontrolled heart failure ( [NYHA] Grade III or IV), hypotension ( systolic blood pressure \< 100 mmHg), severe asthma or (COPD), uncontrolled type I or type II diabetes mellitus ( > 8.5 or 12h fasting plasma glucose > 160 mg/dL at screening), symptomatic peripheral arterial disease or Raynaud's syndrome, untreated pheochromocytoma, current calcium channel blocker use (Non-dihydropyridines such as verapamil) or rhythm control agents such as digoxin and amiodarone. Patients with pacemakers will be excluded
  • MODULE C (BETA BLOCKER): Pregnant or nursing female participants, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test
  • MODULE D: Cardiovascular disease which is deemed limiting exercise readiness by a cardiologist
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
265 participants (estimated)

Study arms

  • Experimental
    Module A (strength training, behavioral intervention)

    Patients undergo strength training sessions twice weekly supervised by a licensed and specialized personal trainer via the internet (e.g., remote access) for 6 months. Patients also wear a FitBit device and receive prompts via email or text on a cell phone or other electronic device to incrementally increase physical activity over 6 months.

    Behavioral: Behavioral Intervention · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Other: Resistance Training

  • Experimental
    Module B (intermittent fasting)

    Patients undergo intermittent fasting for 1 month. This consists of restricting all eating to a consecutive 8-hour time period each day followed by 16 consecutive hours of not eating.

    Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Other: Short-Term Fasting

  • Experimental
    Module C Group I (propranolol)

    Patients receive propranolol PO BID for 3 months.

    Drug: Propranolol · Other: Quality-of-Life Assessment · Other: Questionnaire Administration

  • Active comparator
    Module C Group II (propranolol)

    Patients continue receiving beta-blocker regimen as per SOC for 3 months.

    Drug: Beta-Adrenergic Antagonist · Other: Quality-of-Life Assessment · Other: Questionnaire Administration

  • Experimental
    Module D

    MDS Patients undergo strength training for 6 months.

    Behavioral: Behavioral Intervention · Other: Resistance Training

  • Experimental
    Module E

    Patients undergo resistance training sessions twice weekly supervised by a licensed and specialized personal trainer via the internet (e.g., remote access) for 9 months. Patients also wear a FitBit device and receive prompts via email or text on a cell phone or other electronic device to incrementally increase physical activity over 9 months. Patients also undergo DEXA scans on study and collection of blood samples and bone marrow biopsy (as indicated for clinical care) throughout the trial.

    Behavioral: Behavioral Intervention · Other: Resistance Training

Interventions

  • BehavioralBehavioral Intervention

    Wear a FitBit device and receive prompts for 6 months

    Also known as: Behavior Conditioning Therapy, Behavior Modification, Behavior or Life Style Modifications, Behavior Therapy, Behavioral Interventions, Behavioral Modification, Behavioral Therapy, Behavioral Treatment, Behavioral Treatments

  • DrugBeta blockersStudies of Beta blockersBeta blockers pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Receive beta-blocker regimen as per SOC

    Also known as: Beta Blocker, Beta-Adrenergic Blocking Agent, Beta-Blockers

  • Given PO

    Also known as: 1-[(1-Methylethyl)amino]-3-(1-naphthalenyloxy)-2-propanol

  • OtherQuality-of-Life Assessment

    Ancillary studies

    Also known as: Quality of Life Assessment

  • OtherQuestionnaire Administration

    Ancillary studies

  • OtherResistance Training

    Undergo strength training for 6 months

    Also known as: Strength Training

  • OtherShort-Term Fasting

    Participate in intermittent fasting

    Also known as: Intermittent Fasting, Short-term Intermittent Fasting

06

What researchers measure

Primary outcomes

  1. Changes in immune cell subsets

    Will be assessed by flow cytometry, comparing levels before and after one of three lifestyle interventions (physical exercise, intermittent fasting, beta blocker therapy). Will use a linear mixed model. Since the form of the model is unknown a priori, the power calculations are based on comparing any two timepoints using a two-sided paired t-test. With n=100, we have 80% power (at alpha = 0.05/3) to detect a difference of at least 0.33 standard deviations (SD).

    Time frame: At baseline and at 1 year

Secondary outcomes

  1. Changes in the gut microbiome

    Fecal samples will be collected and compared from group with physical exercise,compared to group doing intermittent fasting).

    Time frame: At 1 and 3 months

  2. Comparison in bone markers

    Will be assessed from intermittent fasting serum samples compared to serum samples of those doing physical exercise.

    Time frame: At 1 and 3 months

  3. Changes in body composition

    Dexa (bone density scan) will be performed at 1 and 3 months

    Time frame: 3 months

  4. Changes in stress

    Significant differences among groups in the mean Perceived Stress Scale (PSS) score, which measures the stress severity perceived by the subjects in the last month. The scale is constituted by 10 items that are self-rated by the subject on a 0-4 Likert scale. The scale minimum total score is 0, the maximum is 40. Higher total scores indicate a worse outcome

    Time frame: At 1 and 3 months

  5. Changes in anxiety

    As assessed by the Generalized Anxiety Disorder 7-item Scale

    Time frame: At 1 and 3 months

  6. Changes in fatigue as assessed by EORTC-LQLQ-FA12

    12-item multidimensional fatigue questionnaire.The scale scores from 1 to 4: 1 ("Not at all"), 2 ("A little"), 3 ("Quite a bit") and 4 ("Very much"). The range is 3. For the raw score, less points are considered to have a better outcome.

    Time frame: At 1 and 3 months

  7. Change in functional status

    basic assessment of physical activity before diagnosis will be compared to one administered at follow up

    Time frame: At 1 and 3 months

  8. Changes in nutritional behavior before and after intermittent fasting

    Will be modeled using a GEE logistic model. Rates of positive nutritional behavior will be compared beween time points.

    Time frame: Up to 5 months

  9. Changes in stress-related biomarkers

    Will be evaluated using a linear mixed model and will be used to compare mean levels between timepoints.

    Time frame: Up to 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Jun 2027, 60 months after the start.

Of 172 non-industry interventional studies with no phase under Multiple Myeloma, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 81. This study's planned 60 months is above that.

Counting every sponsor, half of 186 studies reached it within 38 months; a quarter within 20 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2022
First posted
Apr 5, 2022
StartActual
Jun 28, 2022
Primary completionEst.
Jun 28, 2027
CompletionEst.
Jun 28, 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
175→265
Nov 9, 2026
Eligibility
3 inclusion criteria edited, 6 added; 3 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • AddedModule E: ECOG 0-1
  • EditedMODULE A, B and -C: Have a diagnosis of smoldering multiple myeloma, multiple myeloma or plasma cell leukemia (PCL) or
  • EditedMODULE A, D and DE: (PHYSICAL ACTIVITY): Participant has access to a personal computer or tablet with camera, microphone, speakers and internet access
  • EditedMODULE C: Female participants of child-bearing potential must have a negative pregnancy test at study entry and then agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Male patients with female partners of child-bearing potential should also use adequate contraceptive methods (see above). Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately MODULE D (PHYSICAL ACTIVITY): Patients with MDS not necessitating transfusion therapy at time of enrollment (no transfusion within 8 weeks prior to enrollment) i.e. patients on observation, or receiving growth factors or luspatercept only
  • AddedMODULE E (EX-MT): Have a planned autologous stem cell transplant (ASCT) for front line therapy
  • AddedMODULE E (EX-MT): Be enrolled in the Biorepository and Laboratory Services (BLS) Universal Consent with completed epidemiological questionnaire
  • AddedMODULE E (EX-MT): Report being inactive or low active during the peri-diagnosis and treatment period leading up to study enrollment
  • AddedMODULE E (EX-MT): Participant has access to a personal computer or tablet with camera, microphone, speakers and internet access
  • AddedMODULE E (EX-MT): Receive appropriate medical clearances to exercise
Exclusion criteria
  • EditedMODULE A and E:(PHYSICAL ACTIVITY): Current and symptomatic pathological fracture(s) or severely advanced instability of the musculo-skeletal system that is deemed to making the patient unsafe to participate. This will be assessed by radiologist, a neurosurgeon and/or an orthopedic surgeon, if applicable.
  • EditedMODULE A and E: (PHYSICAL ACTIVITY): Current and symptomatic pathological fracture(s) or severely advanced instability of the musculo-skeletal system
  • EditedMODULE A and E: (PHYSICAL ACTIVITY): Acute bone instability as assessed by whole body low-dose computed tomography and evaluated by an experienced surgeon
Nov 9, 2026
Interventions
Arms added: Module E
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Enrollment 175→265
    Eligibility 3 inclusion criteria edited, 6 added; 3 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • AddedModule E: ECOG 0-1
    • EditedMODULE A, B and -C: Have a diagnosis of smoldering multiple myeloma, multiple myeloma or plasma cell leukemia (PCL) or
    • EditedMODULE A, D and DE: (PHYSICAL ACTIVITY): Participant has access to a personal computer or tablet with camera, microphone, speakers and internet access
    • EditedMODULE C: Female participants of child-bearing potential must have a negative pregnancy test at study entry and then agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Male patients with female partners of child-bearing potential should also use adequate contraceptive methods (see above). Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately MODULE D (PHYSICAL ACTIVITY): Patients with MDS not necessitating transfusion therapy at time of enrollment (no transfusion within 8 weeks prior to enrollment) i.e. patients on observation, or receiving growth factors or luspatercept only
    • AddedMODULE E (EX-MT): Have a planned autologous stem cell transplant (ASCT) for front line therapy
    • AddedMODULE E (EX-MT): Be enrolled in the Biorepository and Laboratory Services (BLS) Universal Consent with completed epidemiological questionnaire
    • AddedMODULE E (EX-MT): Report being inactive or low active during the peri-diagnosis and treatment period leading up to study enrollment
    • AddedMODULE E (EX-MT): Participant has access to a personal computer or tablet with camera, microphone, speakers and internet access
    • AddedMODULE E (EX-MT): Receive appropriate medical clearances to exercise
    Exclusion criteria
    • EditedMODULE A and E:(PHYSICAL ACTIVITY): Current and symptomatic pathological fracture(s) or severely advanced instability of the musculo-skeletal system that is deemed to making the patient unsafe to participate. This will be assessed by radiologist, a neurosurgeon and/or an orthopedic surgeon, if applicable.
    • EditedMODULE A and E: (PHYSICAL ACTIVITY): Current and symptomatic pathological fracture(s) or severely advanced instability of the musculo-skeletal system
    • EditedMODULE A and E: (PHYSICAL ACTIVITY): Acute bone instability as assessed by whole body low-dose computed tomography and evaluated by an experienced surgeon
    Interventions Arms added: Module E
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05312255
Responsible party
Sponsor
First posted
Apr 5, 2022
Start date
Jun 28, 2022
Primary completion
Jun 28, 2027 (estimated)
Completion
Jun 28, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Jens Hillengass
principal investigator · Roswell Park Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Propranolol

Start the discussion